Levetiracetam Tablet
Product Images NDC 50090-7521

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7521). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907521)

Levetiracetam 500 mg oral tablets label by A-S Medication Solutions. The label includes the product name, dosage strength, quantity of 120 tablets, storage instructions at 68 to 77 degrees Fahrenheit, and NDC 50090-7521. Additional administrative details like lot number and QR code are also visible.*

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

Chemical structure of Levetiracetam, showing its molecular configuration with a pyrrolidone ring attached to an ethyl group and an amide functional group.*

FDA Label Image

Figure 1 (Levetiracetam Tablets 2)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The vertical axis represents the percentage of patients, showing approximately 7.4% for Placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

A bar graph showing the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The x-axis represents treatment groups with sample sizes indicated, and the y-axis represents the percentage of patients.*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

A bar graph comparing the percentage of patients who experienced an outcome in two groups: Placebo (14.4% of 104 patients) and Levetiracetam 3000 mg/day (39.4% of 180 patients). The y-axis shows the percentage of patients, and the x-axis lists the two groups with sample sizes.*

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The Placebo group shows 19.6% of patients, whereas the Levetiracetam group shows 44.6%, with an asterisk indicating statistical significance.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

A bar chart comparing the percentage of patients in two groups: Placebo (N=51) with approximately 19.6% and Levetiracetam (N=58) with approximately 43.1%. The y-axis represents the percentage of patients, and the chart indicates a higher response rate in the Levetiracetam group.*

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

A bar graph comparing the percentage of patients in two groups: one receiving Placebo (N=84) with 45.2% and the other receiving Levetiracetam (N=79) with 72.2%. The y-axis represents the percentage of patients from 0% to 100%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.